GlassScriptPhysician profile
Henry Creed Fox
NPI 1407859887
$10,950.49
in general payments reported to CMS, 2019-2025
33 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $680 · 2021: $1,689 · 2022: $1,620 · 2023: $1,611 · 2024: $1,759 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,351.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,168.62 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $957.79 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $788.98 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $734.65 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $624.79 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $582.34 | 2019-2025 | |
| Celgene Corporation | $456.51 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $431.97 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $269.68 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $230.02 | 2019-2023 | Linzess |
| Ardelyx, INC. | $206.68 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $183.11 | 2019-2025 | |
| Allergan, INC. | $150.90 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $146.73 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $125.33 | 2020-2025 | Rebyota |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $113.58 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $92.95 | 2025 | Rezdiffra |
| Genzyme Corporation | $92.20 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $81.93 | 2023-2024 | Voquezna |
| Novo Nordisk INC | $79.92 | 2025 | Wegovy, Saxenda |
| Redhill Biopharma INC. | $74.73 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $65.25 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $58.06 | 2020-2024 | Gimoti |
| Ucb, INC. | $39.99 | 2019-2020 | |
| Boston Scientific Corporation | $36.85 | 2025 | Compliance Endokit, Resolution 360 Ultra Clip |
| Amgen INC. | $35.42 | 2021 | |
| Lilly USA, LLC | $31.77 | 2024 | Omvoh |
| Beone Medicines USA, INC. | $28.59 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $17.64 | 2021 | |
| Mauna Kea Technologies, INC. | $14.80 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.58 | 2022 | |
| Celltrion USA INC. | $14.13 | 2025 | Vegzelma |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,605.77 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.